SHANGHAI – Hua Medicine Ltd. has received a nice endorsement from China's life science investors a month before the country's Spring Festival, closing $25 million in series B financing from some of the leading bio-focused venture capital firms, Frontline Bioventures and TF Capital. The latest financing was led by Ally Bridge Group, with all series A investors – Arch, Venrock, Fidelity, Wuxi Ventures and SAIL – chipping in for a second time.
SHANGHAI – Sirnaomics Inc. is a biopharma straddling the pacific. While one half is in China, with facilities in Suzhou and Guangzhou, it calls Gaithersburg, Md., its headquarters, where the company first got its start seven years ago.
SHANGHAI – Wuxi Pharmatech Inc., of Shanghai, is another step closer to becoming a one-stop shop for drug development with the acquisition of Nextcode Health, a genomic sequencing and bioinformatics company with operations in the U.S. and Iceland.
SHANGHAI – Wuxi Pharmatech Inc., of Shanghai, is another step closer to becoming a one-stop shop for drug development with the acquisition of Nextcode Health, a genomic sequencing and bioinformatics company with operations in the U.S. and Iceland.
SHANGHAI – China's Phagelux Inc. has made a deal with Delaware-registered Iveria Technologies Inc. to acquire several biodegradable polymer delivery systems for its phage technologies being developed for both human and agricultural uses.
SHANGHAI – China's Phagelux Inc. has made a deal with Delaware-registered Iveria Technologies Inc. to acquire several biodegradable polymer delivery systems for its phage technologies being developed for both human and agricultural uses.
SHANGHAI – China's chief economic planning agency has proposed changes to the way medicine prices are set that will allow more room for market forces and do away with government set price caps. Released in a draft discussion document last month, the new policy is expected to come into force Jan. 1, 2015.
SHANGHAI – China's chief economic planning agency has proposed changes to the way medicine prices are set that will allow more room for market forces and do away with government set price caps. Released in a draft discussion document last month, the new policy is expected to come into force Jan. 1, 2015.
SHANGHAI – Eddingpharm Co. Ltd. will develop and commercialize Cardiome Pharma Corp.'s atrial fibrillation drug, Brinavess (vernakalant), paying $1 million up front for the Greater China rights with potential for the Vancouver, British Columbia-based Cardiome to receive $3 million more in regulatory milestone payments.
